Norepinephrine transporter (SLC6A2)
Also known as: NET, SLC6A2, NETT, norepinephrine-transporter
Uptake transporter (SLC6A2) located on noradrenergic terminals, which recycles norepinephrine (adrenaline) into the neurone. It is targeted by SNRIs (venlafaxine, duloxetine) and atomoxetine.
NET inhibition raises synaptic norepinephrine; serotonergic drugs that also inhibit NET (venlafaxine, duloxetine) may cause hypertension through noradrenergic potentiation.
Substrates: norepinephrine (adrenaline), epinephrine.
Inhibitors: venlafaxine, duloxetine, mirtazapine (weak), atomoxetine, desipramine, nortriptyline, bupropion (weak).
Inducers: there are no clinically relevant inducers.
Venlafaxine and duloxetine inhibit both SERT and NET (dual action); mirtazapine has a different mechanism (α2 antagonism) but additive noradrenergic effects.
DailyMed/FDA (NIH/NLM) — approved labels (venlafaxine, duloxetine, mirtazapine); EMC-UK (MHRA) — SmPC
